Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Paper-based electrochemical device for early detection of integrin αvβ6 expressing tumors.
Cinti S, Tomassi S, Ciardiello C, Migliorino R, Pirozzi M, Leone A, Di Gennaro E, Campani V, De Rosa G, D'Amore VM, Di Maro S, Donati G, Singh S, Raucci A, Di Leva FS, Kessler H, Budillon A, Marinelli L. Cinti S, et al. Among authors: di gennaro e. Commun Chem. 2024 Mar 21;7(1):60. doi: 10.1038/s42004-024-01144-z. Commun Chem. 2024. PMID: 38514757 Free PMC article.
New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer.
Costantini S, Madonna G, Di Gennaro E, Capone F, Bagnara P, Capone M, Sale S, Nicastro C, Atripaldi L, Fiorentino G, Parrella R, Montesarchio V, Atripaldi L, Ascierto PA, Budillon A. Costantini S, et al. Among authors: di gennaro e. Int J Mol Sci. 2023 Mar 3;24(5):4922. doi: 10.3390/ijms24054922. Int J Mol Sci. 2023. PMID: 36902351 Free PMC article.
Plasma metabolomics, lipidomics and cytokinomics profiling predict disease recurrence in metastatic colorectal cancer patients undergoing liver resection.
Costantini S, Di Gennaro E, Capone F, De Stefano A, Nasti G, Vitagliano C, Setola SV, Tatangelo F, Delrio P, Izzo F, Avallone A, Budillon A. Costantini S, et al. Among authors: di gennaro e. Front Oncol. 2023 Jan 11;12:1110104. doi: 10.3389/fonc.2022.1110104. eCollection 2022. Front Oncol. 2023. PMID: 36713567 Free PMC article.
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.
Cardone C, De Stefano A, Rosati G, Cassata A, Silvestro L, Borrelli M, Di Gennaro E, Romano C, Nappi A, Zanaletti N, Foschini F, Casaretti R, Tatangelo F, Lastoria S, Raddi M, Bilancia D, Granata V, Setola S, Petrillo A, Vitagliano C, Gargiulo P, Arenare L, Febbraro A, Martinelli E, Ciardiello F, Delrio P, Budillon A, Piccirillo MC, Avallone A. Cardone C, et al. Among authors: di gennaro e. ESMO Open. 2023 Feb;8(1):100748. doi: 10.1016/j.esmoop.2022.100748. Epub 2023 Jan 3. ESMO Open. 2023. PMID: 36603521 Free PMC article. Clinical Trial.
Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Roca MS, Moccia T, Iannelli F, Testa C, Vitagliano C, Minopoli M, Camerlingo R, De Riso G, De Cecio R, Bruzzese F, Conte M, Altucci L, Di Gennaro E, Avallone A, Leone A, Budillon A. Roca MS, et al. Among authors: di gennaro e. J Exp Clin Cancer Res. 2022 Apr 11;41(1):138. doi: 10.1186/s13046-022-02324-2. J Exp Clin Cancer Res. 2022. PMID: 35410264 Free PMC article. No abstract available.
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Roca MS, Moccia T, Iannelli F, Testa C, Vitagliano C, Minopoli M, Camerlingo R, De Riso G, De Cecio R, Bruzzese F, Conte M, Altucci L, Di Gennaro E, Avallone A, Leone A, Budillon A. Roca MS, et al. Among authors: di gennaro e. J Exp Clin Cancer Res. 2022 Mar 3;41(1):83. doi: 10.1186/s13046-022-02295-4. J Exp Clin Cancer Res. 2022. PMID: 35241126 Free PMC article.
69 results